Artificial Intelligence-enhanced Electrocardiogram Diagnoses and Predicts Future

Shanghai Zhongshan Hospital2 sites in 2 countries500,000 target enrollmentMarch 1, 2024

ConditionsElectrocardiogram, Valvular Heart Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Electrocardiogram, Valvular Heart Disease
Sponsor: Shanghai Zhongshan Hospital
Enrollment: 500000
Locations: 2
Primary Endpoint: Progression of valvular heart diseases
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a retrospective study to establish models for the prediction of future valvular heart diseases with artificial intelligence-enhanced electrocardiogram (ECG).

Registry

clinicaltrials.gov

Start Date

March 1, 2024

End Date

May 30, 2024

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Shanghai Zhongshan Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects that received ECG and echocardiography tests during a date frame.

Exclusion Criteria

•Subjects who is younger than 18 years of age.

Outcomes

Primary Outcomes

Progression of valvular heart diseases

Time Frame: 15 years

There would be echo records of subjectes of the study during follow-up. So for subjects with baseline none or mild valvular heart diseases, including mitral regurgitation, aortic regurgitation, and tricuspid regurgitation, there might be some with progression to moderate or severe valvular heart diseases, and some other without this progression. The primary outcome of the study would be the progression of valvular heart diseases from none or mild to moderateor severe, as assessed by echocardiography.